LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Arsenic trioxide (Primary) ; Arsenic trioxide (Primary) ; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Pharmacokinetics; Registrational
- Acronyms LATITUDE
- Sponsors SDK Therapeutics
Most Recent Events
- 26 Dec 2025 New trial record